New treatment approach for pancreatic cancer using modified Gemcitabine
Official title: Development and Testing of a Novel Biospecific using modified Gemcitibine to target and treat Pancreatic Cancer
Funded at Florida Agricultural and Mechanical Univ · NIH-10931534 · Data updated 2026-11-12
This study is testing a new version of a cancer drug to see if it works better for people with pancreatic cancer, especially for Black/African American patients, by helping the medicine get into the cancer cells more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Florida Agricultural and Mechanical Univ NIH-funded |
| Lab location | 1 site (Tallahassee, United States) |
| Project start | September 19, 2018 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $37,565 |
| NIH project number | 5U54CA233396-07 |
| Project ID | NIH-10931534 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include Black/African American individuals diagnosed with pancreatic ductal adenocarcinoma.
✕Less likely to help
Patients with other types of cancer or those who do not have pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for pancreatic ductal adenocarcinoma (PDAC), a highly aggressive cancer with low survival rates, particularly among Black/African American patients. The approach involves modifying Gemcitabine to enhance its effectiveness by improving its transport into cancer cells and reducing its breakdown. The researchers will test this modified drug in patient-derived organoid models to evaluate its efficacy compared to traditional treatments. By targeting specific receptors on cancer cells, this research aims to provide a more effective therapy for patients suffering from this challenging disease.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: While this approach is innovative, similar strategies targeting specific cancer receptors have shown promise in other types of cancer treatments.
Where this research is happening
-
Florida Agricultural and Mechanical Univ
Tallahassee, United States Active
Researchers
- Principal investigator: Agyare, Edward Kwasi — Florida Agricultural and Mechanical Univ
- Study coordinator: Agyare, Edward Kwasi
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.